Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Arbutus Biopharma Corp (ABUS)
|
Add to portfolio |
|
|
|
| Price: |
$3.17
| | Metrics |
| OS: |
167.6
|
M
| |
-54
|
% ROE
|
| Market cap: |
$531
|
M
| |
-61
|
% ROIC
|
|
Net cash:
|
$164
|
M
| |
$0.98
|
per share
|
|
EV:
|
$368
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($75.6)
|
M
| |
|
|
|
EBIT
|
($76.9)
|
M
| |
|
|
| EPS |
($0.47)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 39.0 | 11.0 | 6.9 | 6.0 | 5.9 | 10.7 | 1.5 | 23.3 |
| Revenue growth | 255.1% | 58.9% | 15.0% | 1.1% | -44.4% | 617.6% | -93.6% | 55.7% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | -150.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 39.0 | 11.0 | 6.9 | 156.1 | 5.9 | 10.7 | 1.5 | 23.3 |
| Gross margin | 100.0% | 100.0% | 100.0% | 2596.8% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 84.4 | 65.5 | 49.3 | 57.6 | 57.9 | 62.7 | 61.3 | 51.5 |
| General and administrative | 17.8 | 17.1 | 14.8 | 17.7 | 16.0 | 16.1 | 39.4 | 26.4 |
| EBIT | -65.5 | -73.5 | -60.3 | -93.9 | -70.2 | -70.1 | -100.3 | -55.3 |
| EBIT margin | -167.8% | -669.1% | -872.0% | -1561.6% | -1180.4% | -655.4% | -6726.5% | -237.4% |
| Pre-tax income | -60.6 | -76.2 | -63.7 | -166.4 | -61.3 | -108.7 | -489.2 | -78.9 |
| Income taxes | 4.4 | 0.0 | 0.0 | -12.7 | -4.3 | -24.3 | -105.0 | -16.2 |
| Tax rate | | 0.0% | 0.0% | 7.6% | 7.0% | 22.4% | 21.5% | 20.5% |
| Net income | -69.5 | -88.4 | -75.9 | -164.9 | -67.2 | -85.3 | -384.2 | -62.7 |
| Net margin | -178.0% | -804.4% | -1097.3% | -2742.8% | -1129.5% | -797.4% | -25765.5% | -269.5% |
| |
| Diluted EPS | ($0.46) | ($0.83) | ($1.00) | ($2.89) | ($1.21) | ($1.56) | ($7.24) | ($1.38) |
| Shares outstanding (diluted) | 150.9 | 106.2 | 75.8 | 57.1 | 55.3 | 54.7 | 53.1 | 45.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|